As per recent reports, it has been declared that US Patent Office has granted patent to drug firm Venus Remedies for its new antibiotic. It has been revealed that the antibiotic targets infection, which in due course time has developed resistance against drugs.
The company has claimed that the antibiotic product, CSE 1034, has proven to be effective in a majority of drug resistant infection, including those that are incurred due to superbugs.
Venus Medical Research Centre Vice President Mufti Suhail Sayeed said: "The US patent of CSE 1034... Is a landmark development for initiating the process of commercialization of this novel drug, designed specifically to target growing bacterial resistance mechanisms".
Nevertheless, the company affirmed that the antibiotic is of great importance across the world as there is a growing demand of ways to tackle the problem of drug resistant infections, especially in India.
Moreover, the company added that a major increase in the problem has been faced due to the emergence of superbugs like carbapenemase resistant Metallobetalactamses.
The Company asserted that due to an increase in the demand of such drugs, which can combat infectious diseases, regulatory agencies are approving antibiotic drugs fast. Latest reports suggest that the drug is expected to be launched in India under the name of Elores.